Brookstone Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Brookstone Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$304K	Buy	582 +82	+16%	+$42K	﹤0.01%	1106
2026 Q2	$248K	Buy	500 +3	+0.6%	+$1.33K	﹤0.01%	1170
2026 Q1	$222K	Sell	497 -38	-7%	-$17.7K	﹤0.01%	1132
2025 Q4	$243K	Sell	535 -4	-0.7%	-$1.72K	﹤0.01%	1054
2025 Q3	$211K	Buy	+539	New	+$225K	﹤0.01%	1082
2025 Q2	–	Sell	-2,264	Closed	-$1.1M	–	1100
2025 Q1	$1.1M	Sell	2,264 -56	-2%	-$26.1K	0.02%	532
2024 Q4	$934K	Sell	2,320 -2	-0.1%	-$927	0.01%	550
2024 Q3	$1.08M	Sell	2,322 -169	-7%	-$81.2K	0.02%	508
2024 Q2	$1.22M	Buy	2,491 +123	+5%	+$53.4K	0.02%	464
2024 Q1	$990K	Buy	2,368 +237	+11%	+$100K	0.02%	493
2023 Q4	$867K	Sell	2,131 -1,206	-36%	-$446K	0.02%	488
2023 Q3	$1.22M	Buy	3,337 +1,208	+57%	+$422K	0.03%	393
2023 Q2	$720K	Sell	2,129 -34	-2%	-$11.5K	0.01%	496
2023 Q1	$709K	Sell	2,163 -232	-10%	-$69.6K	0.01%	522
2022 Q4	$695K	Buy	2,395 +1,681	+235%	+$512K	0.01%	515
2022 Q3	$207K	Buy	+714	New	+$205K	﹤0.01%	743
2021 Q3	–	Sell	-1,151	Closed	-$228K	–	794
2021 Q2	$228K	Buy	+1,151	New	+$241K	﹤0.01%	652
2020 Q3	–	Sell	-4,055	Closed	-$1.18M	–	472
2020 Q2	$1.18M	Buy	+4,055	New	+$1.1M	0.07%	158
2015 Q4	–	Sell	-13	Closed	-$1K	–	866
2015 Q3	$1K	Hold	13	–	–	﹤0.01%	1857
2015 Q2	$2K	Buy	+13	New	+$1.64K	﹤0.01%	1837

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $39.3B AUM 31.81% 1-Year Est. Return

ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $57.1B AUM 43.46% 1-Year Est. Return

Brookstone Capital Management's VRTX Position: Q3 2026 in Review

Brookstone Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 16% in Q3 2026, buying an estimated $42K and bringing the position to 582 shares worth $304K. The position accounts for ﹤0.01% of the portfolio, ranked #1106.

Brookstone Capital Management first reported a position in VRTX in Q2 2015 and has held it in 20 quarters since. The position peaked at $1.22M in Q3 2023. 810 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Brookstone Capital Management held 582 shares of Vertex Pharmaceuticals worth $304K as of Q3 2026.
Brookstone Capital Management bought 82 Vertex Pharmaceuticals shares in Q3 2026, an estimated $42K.
Vertex Pharmaceuticals made up ﹤0.01% of Brookstone Capital Management's portfolio in Q3 2026, its #1106 holding.
Brookstone Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2015 and has held it in 20 quarters since.
Brookstone Capital Management's Vertex Pharmaceuticals position peaked at $1.22M in Q3 2023.
810 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Brookstone Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.